MAY 23, 2018 1:10 AM PDT

Potential Treatment for Triple-Negative Breast Cancer

WRITTEN BY: Nouran Amin


Recent research published in the Journal of Clinical Investigation examined the drug Dacogen (decitabine), which was observed to target the growth of cancer and was effective in treating tumors resistant to chemotherapy. The Food and Drug Administration has approved decitabine for treating bone marrow and blood cancers

“Patients whose tumor does not respond well to chemotherapy are known to be at significantly increased risk of recurrent breast cancer and death,” expalins Judy Boughey, MD, a general surgeon at the Cancer Center at the Mayo Clinic in Rochester, Minnesota. “Therefore, our focus is to identify new treatment options for these patients.”

 

 

Breast cancer is responsible for 30 percent of new cancer diagnoses in women in the United States each year. About 1 in 8 women will be diagnosed with invasive breast cancer at some point in their lives. The majority of breast cancers are invasive, which means that the cancer spreads and grows in healthy tissues. This is in comparison to noninvasive breast cancers which remain in the lobules or the milk ducts.

For triple-negative breast cancer (TNBC), the National Breast Cancer Foundation describes this particular cancer as the cells of the tumor that do not include the three most common forms of receptors, which is the HER-2 receptor, estrogen receptors, and progesterone receptors.

Investigators have been studying the potential use for decitabine in solid tumors, however the results are more encouraging than previous trials, exapalisn Cynthia Zahnow, PhD, an associate professor of oncology at the Johns Hopkins University School of Medicine. “We [researchers at Johns Hopkins] published a paper back in 2012 showing that these low doses of these drugs do have an effect in cancer tumors,” she explains, referencing a study published in March 2012 in the journal Cancer Cell.

The study suggested that the therapy could create an anti-tumor “memory” response, and inhibit growth of cancer stem-like cells. In the Mayo research study, the researchers used living xenografts (tissue from breast tumor cells). They found that decitabine can remarkably inhibit the growth of triple-negative breast cancers, however, the response was dependent on the presence of certain critical proteins known as DNA methyl transferase proteins (DNMT), which are present in a certain subset of triple-negative breast cancers.

“If researchers can truly select patients that have high levels of DNMT and show that these drugs are more effective in them, that’s a fantastic discovery,” notes Dr. Zahnow.

Sources: Journal of Clinical Investigation

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 20, 2020
Cell & Molecular Biology
Revealing the Structure of Hallucinogens Bound to Their Receptor
SEP 20, 2020
Revealing the Structure of Hallucinogens Bound to Their Receptor
Recent studies have demonstrated that hallucinogenic drugs like LSD, psilocybin, and mescaline have therapeutic potentia ...
SEP 21, 2020
Drug Discovery & Development
Metformin Does Not Work in All Type 2 Diabetics
SEP 21, 2020
Metformin Does Not Work in All Type 2 Diabetics
Although metformin is the first-line drug for type-2 diabetics, research shows that it is not always effective for all t ...
OCT 12, 2020
Microbiology
Researchers May Have Found a Way to Cure Rotavirus Infections
OCT 12, 2020
Researchers May Have Found a Way to Cure Rotavirus Infections
Rotaviruses are very contagious. They are the most common cause of diarrhea in children and are estimated to cause about ...
OCT 23, 2020
Drug Discovery & Development
FDA Gives Full Approval to Remdesivir to Treat COVID-19
OCT 23, 2020
FDA Gives Full Approval to Remdesivir to Treat COVID-19
The US Food and Drug Administration (FDA) has approved antiviral drug Remdesivir, sold under the name ‘Velkury&rsq ...
NOV 18, 2020
Technology
Using Machine Learning to Build Chemical Libraries
NOV 18, 2020
Using Machine Learning to Build Chemical Libraries
Using machine learning in drug discovery is no longer a novel procedure and has been well documented in recent literatur ...
NOV 18, 2020
Drug Discovery & Development
Hepatitis C Drugs May Be Involved Coronavirus Treatment
NOV 18, 2020
Hepatitis C Drugs May Be Involved Coronavirus Treatment
At the present moment, there are no inhibitors that target protease activity of the novel SARS-CoV-2. The main proteases ...
Loading Comments...